Context Matters and IHS Markit Integration Featured in Pharmaceutical Commerce

Two drug-pricing firms combine data sets for a deeper picture on reimbursement decisions

Context Matters and IHS Markit provide analytics on pricing strategies

Pharmaceutical Commerce provides coverage on the new data integration collaboration between Context Matters and IHS Markit. The integration is driving the new combined pricing strategy tool PriceCurrents.

 

When Measuring European Regulatory Approval, the Timestamp Matters

pharmaphorum recently published an article written by our Founder and CEO Yin Ho and Research Analyst Daniel Sanchez: "When Measuring European Regulatory Approval, the Timestamp Matters." The article looks at cycle times in regulatory decisions and how they are being measured in the US and Europe. A cycle time measures the time from the date of submission, through date of approval. We noticed that some of the analyses involving the European Medicines Agency (EMA)’s cycle time used an inappropriate endpoint, resulting in cycle times that looked two months shorter than they actually are.

Overcoming the Market Access Hurdle through Better Planning of Clinical Trials

PharmaPhorum recently published an article written by our Founder and CEO Yin Ho and Associate Director of Data and Analytics Rachel Jao, "Overcoming the Market Access Hurdle through Better Planning of Clinical Trials." The article points out that though regulatory approval is still a key step in getting a drug to market, it no longer guarantees market access. The authors discuss how clinical-trial design and the implications on reimbursement can help companies make better use of their resources and expedite the path to a successful drug launch.

Picking Winners: Data Mining for Drug Discovery - CM Featured in Fierce Biotech

Fierce Biotech recently featured Context Matters in an e-book "Picking Winners: Data Mining for Drug Discovery". Our founder and CEO Yin Ho discusses how biotech and pharma companies are starting to understand the importance of reimbursement data and the insights that can be learned from following these patterns early in the drug development process.

Keeping the Fast Lane Open - DDN News Feature on Our FDA Breakthrough Designation Research

Drug Discovery News recently did a feature story, "Keeping the Fast Lane Open" that used our research and thinking from our three-part series "Life in the Fast Track." Since there has been a lot of discussion recently about the FDA’s new “Breakthrough Therapy” designation, we thought it would be interesting to look at some previous FDA fast lanes to see if they have actually made a difference in the speed and process of bringing drugs to market.

Pharmaceutical Trade Groups Endorse Data Sharing, with Conditions - Our CEO, Yin Ho, in Specialty Pharmacy Times

The trending topic of data transparency has been making news recently. The European Federation of Pharmaceutical Industries (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) have agreed to make their clinical trial data more readily available for public inquiry. Our Founder and CEO, Yin Ho, was asked to comment on this recently, in a Specialty Pharmacy Times piece, "Pharmaceutical Trade Groups Endorse Data Sharing, with Conditions."

FierceBiotechIT Discusses Pfizer/Context Matters Collaboration on PRO Usage in Diabetes Clinical Trials Study

FierceBiotechIT recently wrote about our analysis of online data, researched by the team here at Context Matters in collaboration with Pfizer, that found only 7.4% (47 trials) of 650 Phase 3 and Phase 2/3 clinical trials for diabetes treatments included patient-reported outcomes.